WO2012005240A1 - 腸内腐敗物質の低減作用を有するビフィズス菌 - Google Patents
腸内腐敗物質の低減作用を有するビフィズス菌 Download PDFInfo
- Publication number
- WO2012005240A1 WO2012005240A1 PCT/JP2011/065350 JP2011065350W WO2012005240A1 WO 2012005240 A1 WO2012005240 A1 WO 2012005240A1 JP 2011065350 W JP2011065350 W JP 2011065350W WO 2012005240 A1 WO2012005240 A1 WO 2012005240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentration
- bifidobacteria
- reducing
- intestinal
- microorganisms
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 71
- 241000186000 Bifidobacterium Species 0.000 title claims abstract description 46
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 46
- 230000000694 effects Effects 0.000 title abstract description 40
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims abstract description 66
- 244000005700 microbiome Species 0.000 claims abstract description 57
- 210000002966 serum Anatomy 0.000 claims abstract description 27
- 238000012216 screening Methods 0.000 claims abstract description 10
- 241000186012 Bifidobacterium breve Species 0.000 claims description 47
- 241000894006 Bacteria Species 0.000 claims description 41
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 41
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 41
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 25
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229960004799 tryptophan Drugs 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 3
- 235000014048 cultured milk product Nutrition 0.000 claims description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 43
- 210000000936 intestine Anatomy 0.000 abstract description 19
- 230000010757 Reduction Activity Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 21
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 21
- 230000009467 reduction Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 13
- 241001608472 Bifidobacterium longum Species 0.000 description 12
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229940074386 skatole Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001341 hydroxy propyl starch Substances 0.000 description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 xyl sulfate Chemical compound 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000545263 Salacia <hydroid> Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a method for improving the state of enteric bacteria. More specifically, the present invention relates to selection of useful microorganisms that reduce indole compounds that cause rot odor caused by intestinal bacteria, and the selected microorganisms.
- Non-patent Document 1 An increasing number of people complain of symptoms such as repeated constipation and diarrhea, stomach up, and outgassing due to disordered eating habits, irregular lifestyles, and stress. These symptoms are thought to be due to the influence of the intestinal environment, in other words, the prevalence of spoilage bacteria in the intestinal flora.
- the intestinal microflora produces spoiled odor components such as indole and its derivatives from tryptophan under anaerobic conditions.
- Several studies have been conducted on the relationship between such intestinal flora and the production of spoilage products (Non-patent Document 1).
- Indole is also considered to be produced from tryptophan by intestinal spoilage bacteria, absorbed from the intestine, metabolized to indoxyl in the liver, and further combined with sulfuric acid to become indoxyl sulfate. In healthy humans, indoxyl sulfate is excreted in the urine, but it is considered to cause complications such as uremia in dialysis patients and the like (Non-patent Document 2).
- Patent Document 1 uses a bifidobacterum / thermophilum having an indole-reducing ability.
- Patent Document 2 describes that an extract or finely ground product of a Salacia plant is used in combination with lactic acid bacteria and / or bifidobacteria to improve the intestinal environment.
- Patent Document 3 describes that a composition containing propionic acid bacteria promotes the growth of bifidobacteria in the intestine and prevents the release of malodorous gases. It has also been reported that inulin and oligosaccharides are useful for improving the intestinal bacterial flora (Non-patent Document 3).
- the present invention has an object to effectively reduce enteric spoilage substances by effectively using highly safe and useful microorganisms.
- the above-mentioned spoilage substances are mainly produced in the large intestine, and examples of microorganisms (bacteria species) that are dominant in the large intestine include lactic acid bacteria and bifidobacteria (genus Bifidobacterium).
- This bifidobacteria has been used for food since ancient times as a microorganism that exhibits useful functions in vivo, and has a track record of eating experience. Therefore, it is a first object of the present invention to select microorganisms (strains) that can effectively reduce spoilage substances from bifidobacteria predominate in the human body (intestines).
- the present invention provides a second in vitro and in vivo system suitable as a verification or search system for the action effect of a substance or microorganism that reduces spoilage substances generated in vivo (in the intestine). Let it be an issue.
- the present inventor completed the present invention by isolating strains that effectively reduce intestinal spoilage substances from lactic acid bacteria and bifidobacteria as highly safe and useful microorganisms based on the screening method of the present invention. It was.
- the inventor of the present application uses a buffer solution to proliferate bacterial cells when screening in vitro as a verification system for the action effect of a substance or microorganism that reduces spoilage substances generated in the living body (intestine).
- the inventor of the present application is characterized in that the reaction solution is set (designed) to the amount of glucose that is the minimum energy necessary for the reduction of spoilage substances under conditions where lactic acid bacteria and bifidobacteria hardly grow.
- An in-vitro selection method and / or evaluation method for microorganisms (such as lactic acid bacteria and bifidobacteria) that reduce spoilage substances produced by intestinal bacteria was established.
- the inventor of the present application uses a mouse as a verification system for the action effect of a substance or a microorganism that reduces spoilage substances generated in vivo (in the intestine), from the serum, using a mouse.
- a mouse was studied to measure indoxyl sulfate.
- the present inventor added fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) and tryptophan (L-Tryptophan) to the diet (powder diet), raised the mouse, and indoxyl sulfate in the serum.
- a method for selecting and / or evaluating microorganisms such as lactic acid bacteria and bifidobacteria
- concentration such as lactic acid bacteria and bifidobacteria
- strains that can effectively reduce spoilage substances
- the present inventor first selects bifidos that are generally dominant in the human body (intestines) as highly safe and useful microorganisms. Focusing on the fungus, a total of 196 strains, 32 strains of Bifidobacterium ifbreve, 92 strains of Bifidobacterium longum, 72 strains of Bifidobacterium adolescenti, were screened and evaluated by in vitro, and 9 strains were preliminarily selected.
- the present invention includes medicines and foods containing Bifidobacterium as an active ingredient, which has a strong action of reducing the indole selected above and shows a reduction action of indoxyl sulfate in serum.
- Bifidobacterium breve (B. breve) of the present invention is a human-derived strain and has an excellent effect of significantly reducing indole and indoxyl sulfate in serum in a system in which the strain itself does not grow.
- B. breve which has long been edible, has high safety, and the bifidobacteria OLB6129 of the present invention can be widely applied and applied in the food and pharmaceutical fields.
- Bifidobacterium breve live bacteria
- Bifidobacterium longum live bacteria
- B. breve OLB6129 live bacteria concentration on the serum indoxyl sulfate concentration after oral administration of B. breve OLB6129 (live bacteria) to mice Number of colonies of B.Bbreve OLB6129 in feces (Fecal) and caecal contents (cecal) detected on TOS propionate agar medium
- microorganisms that are dominant in the large intestine include Lactobacillus and Bifidobacterium (Bifidobacterium spp.). Bifidobacteria have been used in food since ancient times as microorganisms that exhibit useful functions in vivo. In addition, bifidobacteria are said to have an intestinal regulating action, and are also used for intestinal preparations, etc., which also helps improve the intestinal flora, through the improvement of the intestinal environment, diarrhea suppression, prevention of rough skin, hay fever improvement, It is also said to be effective for immunity Taoism.
- the present inventor first uses a buffer solution to reproduce conditions under which microorganisms are difficult to grow, The evaluation method of the reduction effect (reduction ability) was examined. By adopting such conditions, it is possible to select excellent microorganisms under conditions closer to the intestinal environment, in which spoilage substances can be removed even if the microorganisms do not grow. For example, the components and concentration of the reaction solution can be determined under conditions in which the target microorganism hardly grows and under conditions that set the minimum energy necessary for reducing spoilage substances.
- the amount of the medium component serving as an energy source can lower the concentration of glucose, lactose, fructose, etc., compared to the normal culture conditions of the target microorganism, and remove intestinal spoilage substances.
- a degree of 0.3 to 0.7 (w / v)% can be applied.
- fructooligosaccharide (FOS) was added to the diet.
- the reduction effect of indoxyl sulfate in the solution was confirmed.
- the mouse generally used in animal experiments is a young healthy individual, the amount of spoilage substances in the living body is suppressed to a very small amount and often falls below the detection limit. Therefore, in the present invention, in an animal experiment using a mouse, tryptophan (L-Tryptophan), which is a precursor of indole in vivo, is added to the diet (powder), and the baseline of indole generated in vivo is determined. Attempts to increase showed a significant increase in the indole baseline. In other words, the concentration of indoxyl sulfate in serum, which is an index (marker) of spoilage substances, can be evaluated stably and reliably. And the reduction
- fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) and tryptophan (L-Tryptophan) are added to a diet (powder) at a predetermined concentration, and a general mouse (for animal experiments) is added. It can be reared and the concentration of indoxyl sulfate in serum can be evaluated. At this time, the concentration of the total amount of fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) is 0.5 to 20 (w / v)%, preferably 0.5 to 15 (w / v)%, more preferably , 0.5 to 10 (w / v)%.
- fructooligosaccharide (FOS) concentration is set to 0.5 (w / v)%, the viability of B. breve OLB6129 is significant as the number of viable bacteria in feces. Has been confirmed to improve.
- the concentration of tryptophan is set to 1 to 4 (w / v)%, preferably 1.5 to 3.5 (w / v)%, and more preferably 2 to 3 (w / v)%.
- microorganisms such as lactic acid bacteria and bifidobacteria
- bifidobacteria microorganisms of the genus Bifidobacterium
- microorganisms that reduce intestinal spoilage substances The inventor of the present application generally chooses microorganisms (strains) that can effectively reduce spoilage substances as microorganisms that reduce intestinal spoilage substances.
- strains The study was conducted on lactic acid bacteria and bifidobacteria, particularly bifidobacteria, which are dominant in (1).
- a bifidobacteria a total of 196 strains including 32 strains of B. breve, 92 strains of B. longum, and 72 strains of B. adolescentis were screened and evaluated in vitro. As a result, a total of 9 strains of 6 strains of B. breve and 3 strains of B. longum were selected.
- the selected nine strains were subjected to animal experiments and evaluated in vivo. As a result, a strain that exhibits the effect of reducing indole in the intestine was selected.
- the screened Bifidobacterium breve OLB6129 (B. breve OLB6129) is an independent administrative agency, National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (Contact: Postal Code 305-8566, Tsukuba 1-1-1, Higashi, Tsukuba, Japan Deposited on May 26, 2010 at Center Center No. 6), and this microorganism is deposited under the accession number as FERM BP-11257.
- microorganisms that reduce intestinal spoilage 4-1 Food containing microorganisms that reduce intestinal spoilage substances
- the microorganisms (such as lactic acid bacteria and bifidobacteria, preferably B. breve OLB6129) that reduce the intestinal spoilage substances of the present invention can be added to foods. That is, as the food of the present invention, any food to which microorganisms that reduce intestinal spoilage substances are added can be mentioned, and preferably fermented milk products or fermented milk drinks to which microorganisms that reduce intestinal spoilage substances are added. More preferably, a microorganism (B.
- fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) can be mentioned. It is known that GOS can be used in the same way as FOS (http://www.nyusankin.or.jp/scientific/hosono_3.html).
- the addition amount of fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) is 0.5 to 20 (w / v)%, preferably 0.5 to 15 (w / v)% as the total concentration. Preferably, it can be set to 0.5 to 10 (w / v)%.
- the food containing a microorganism (Lactic acid bacteria, bifidobacteria, etc., preferably B. breve OLB6129) that reduces intestinal spoilage substances of the present invention is a health health for preventing or improving dialysis complications for renal dialysis patients. It can be applied as food (functional food).
- the pharmaceutical product containing a microorganism that reduces the intestinal spoilage substance of the present invention is a reducing agent for intestinal spoilage substance or prevention of dialysis complications for renal dialysis patients. It can be applied as an agent or an improving agent. Furthermore, the pharmaceutical product of the present invention can be applied as a stomach tension improving agent.
- the pharmaceutical product of the present invention can be made into appropriate dosage forms such as powders, granules, tablets, capsules, and liquids.
- the pharmaceutical of the present invention may contain fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS).
- the content of fructooligosaccharide (FOS) and / or galactooligosaccharide (GOS) is 0.5 to 20 (w / v)%, preferably 0.5 to 15 (w / v)% as the total concentration. Preferably, it can be set to 0.5 to 10 (w / v)%.
- excipients include starch, lactose, sucrose, methylcellulose, carboxymethylcellulose, sodium alginate, calcium hydrogen phosphate, synthetic aluminum silicate, microcrystalline cellulose, polyvinylpyrrolidone (PVP), and hydroxypropyl starch (HPS).
- binder include starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinyl pyrrolidone (PVP), gum arabic powder, gelatin, glucose, sucrose, and water / ethanol solutions thereof.
- disintegrant examples include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, microcrystalline cellulose, hydroxypropyl starch, and calcium phosphate.
- lubricants for example, carnauba wax, light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, synthetic magnesium silicate, hardened oil, hardened vegetable oil derivative (Sterotex HM), sesame oil, white beeswax, titanium oxide , Dry aluminum hydroxide / gel stearic acid, calcium stearate, magnesium stearate, talc, calcium hydrogen phosphate, and sodium lauryl sulfate.
- the pharmaceutical product of the present invention is desirably administered orally, and bifidobacteria have established safety, so that any amount can be administered.
- the dosage can be as much as 1 billion bifidobacteria per day.
- the number can be from 500 to 500 billion, and preferably from 10 to 500 billion.
- glucose is set to 0.7 (w / v)% or less, preferably 0.6 (w / v)% or less, and more preferably 0.55 (w / v)% or less.
- glucose is set to, for example, 0.3 (w / v)% or more, preferably 0.4 (w / v)% or more, and more preferably 0.45 (w / v)% or more.
- the composition of the reaction solution was determined for the other components.
- the composition of the reaction solution should be 20 ⁇ g each of phenol, p-cresol, indole, skatole, 0.1 M Bis-Tris, 0.75 mM magnesium sulfate (MgSO 4 ), and 0.5 (w / v)% glucose.
- PH is about 6.5.
- Example 1 Selection of microorganisms capable of reducing spoilage substances "in vitro test" A total of 199 B. breve strains, 93 B. longum strains, and 72 B. adolescentis 72 strains were statically cultured, and two B. breve strains and one B. longum strain grew extremely. It was late. Therefore, these three strains were excluded from the experiment. Finally, a total of 196 strains (evaluation / selection) of 32 strains of B. breve, 92 strains of B. longum and 72 strains of B. adolescentis were selected. did.
- this supernatant was extracted twice with diethyl ether, and the extract was made up to 5 ml, and the solution was subjected to gas chromatography (GC) to indole, phenol, p-cresol, The concentration of skatole was measured (detected).
- GC gas chromatography
- GC-2014 Shiadzu
- TC-1 GL Sciences Inc.
- ID 0.25mm
- L 30mm
- dF 0.25mm
- column temperature 60 -170 °C (increased by 5 °C / min)
- 170-250 °C increased by 20 °C / min
- carrier gas nitrogen
- flow rate 71.3 ml / min
- injector temperature 240 °C
- detector temperature 250 °C
- injection volume 1 ⁇ l.
- Table 1 32 strains of B. breve
- Table 2 92 strains of B. longum
- Table 3 72 strains of B. adolescentis
- strains whose reference numbers begin with “JCM” are stored in the following storage organizations.
- Example 2 Selection of microorganisms capable of reducing spoilage substances "in vivo test (animal experiment)" Nine strains selected in Example 1 above were screened (evaluated and selected) by animal experiments (in vivo tests).
- the strain (live bacteria) to be administered to the mice was selected (screened) by an in vitro test. Specifically, 6 strains of B. breve (MEP22023004, OLB6129, MEP22023007, MEP22023012, MEP22023015, MEP22023016) and 3 strains of B. longum (MEP22023039, MEP22023061, MEP22023078) were selected. Then, an equal volume of physiological saline was used as a control group, and the administration group of a predetermined strain (live bacteria) was compared with the effect of reducing spoilage substances. The results are shown in FIG. 1 (6 strains of B. breve) and FIG. 2 (3 strains of B. longum).
- mice Effect of presence or absence of FOS administered to living body on reduction effect of spoilage substances
- SLC Balb / c mice
- Table 5 the mice were divided into 4 groups based on body weight. Suspension of B. breve OLB6129 (viable bacteria) in water and physiological saline, and suspension of B. breve OLB6129 (viable bacteria) in saline and physiological saline with FOS added in 2 weeks Orally administered in the morning.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
ヒトの生体内(腸内)で生成される腐敗物質は発ガンや老化を促進することが知られており、生体内の腐敗物質を積極的に低減できれば、ヒトの健康に寄与できると考えられる。主として大腸内で生成される腐敗物質として、フェノール、p-クレゾール、インドール、スカトール、アンモニアなどを列挙できる。これらの腐敗物質のうち特に、インドールやスカトールなどが悪臭成分であり、また、健康に悪影響を及ぼす可能性のある成分であることから、インドールやスカトールの低減が望まれている。
2-1.腸内腐敗物質を低減させる微生物の in vitro でのスクリーニング又は予備的なスクリーニング
微生物を使用して、腸内腐敗物質(腸内で生成され、悪臭成分などを発生する物質)を腸内環境で低減させるためには、その特定の微生物が腸内で優先的に存在することが重要である。つまり、そのような微生物が備えるべき性質として、腸内環境に適応した条件への耐性が必要となる。
当初には、動物実験を実施してin vivoにより、血清中のインドキシル硫酸の低減効果を十分に確認できなかった。血清中のインドキシル硫酸の低減効果は、腸内で発揮されることが期待されるが、生体内に微生物(菌体)が投与されても、腸内に到達する前に、その大部分が死滅している可能性や、腸内に到達した後に、それが安定して維持(保持)されていない可能性が考えられた。そこで、本願発明では、生体内に微生物が投与された後に、その生残性や安定性などの向上に寄与することを期待して、フラクトオリゴ糖(FOS)を食餌へ添加してみたところ、血清中のインドキシル硫酸の低減効果を確認できた。
本願発明者は、腸内腐敗物質を低減させる微生物として、腐敗物質を効果的に低減できる微生物(菌株)を選抜する目的から、一般的にヒトの生体内(腸内)で優勢とされる乳酸菌やビフィズス菌、特にビフィズス菌を対象として検討した。そして、ビフィズス菌として、B. breveの32菌株、B. longumの92菌株、B. adolescentisの72菌株の合計で196菌株について、スクリーニングを実施して、in vitroで評価した。その結果として、B. breveの6菌株と、B. longumの3菌株の合計で9菌株を選抜した。
4-1.腸内腐敗物質を低減させる微生物を含有する食品
本願発明の腸内腐敗物質を低減させる微生物(乳酸菌やビフィズス菌など、好ましくは、B. breve OLB6129)は、食品に添加することができる。つまり、本願発明の食品として、腸内腐敗物質を低減させる微生物を添加した任意の食品を挙げることができ、好適には、腸内腐敗物質を低減させる微生物を添加した発酵乳製品又は発酵乳飲料を挙げることができ、さらに好適には、腸内腐敗物質を低減させる微生物(B. breve OLB6129)、並びにフラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)を添加した発酵乳製品又は発酵乳飲料を挙げることができる。なおGOSは、FOSと同様に利用できることが知られている(http://www.nyusankin.or.jp/scientific/hosono_3.html)。また、フラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)の添加量は、総量の濃度として、0.5~20(w/v)%、好適には、0.5~15(w/v)%、より好適には、0.5~10(w/v)%に設定することができる。
本願発明の腸内腐敗物質を低減させる微生物(乳酸菌やビフィズス菌など、好ましくは、B. breve OLB6129)を含む医薬品は、腸内腐敗物質の低減剤、又は腎臓透析患者用の透析合併症の予防剤又は改善剤として適用することができる。さらに、本願発明の医薬品は、お腹の張りの改善剤としても適用することができる。
まず、反応溶液の組成では、ビフィズス菌が殆ど増殖せず、インドール(腸内腐敗物質の指標)の低減効果を発揮し、その効果を明確に評価できるように、反応溶液の組成を決定した。
B. breveの34菌株、B. longumの93菌株、B. adolescentisの72菌株の合計で199菌株について、静置培養したところ、B. breveの2菌株、B. longumの1菌株で生育が極端に遅かった。そこで、これら3菌株を実験の対象外とし、最終的には、B. breveの32菌株、B. longumの92菌株、B. adolescentisの72菌株の合計で196菌株について、スクリーニング(評価・選抜)した。
上記の実施例1で選抜した9菌株を動物実験(in vivo試験)により、スクリーニング(評価・選抜)した。
[実験手順]
Balb/cマウス(SLC, ♀, 6-week-old)を一週間で馴化した後に、表4のように、体重に基づいて 4群に分け、それぞれの群について、生理食塩水と生理食塩水の B. breve OLB6129(生菌)の懸濁液を、2週間で連続して午前中に経口投与した。馴化期間には全群に飼料(粉末CRF-1/FOS(和光純薬工業(株)):10(w/v)%、L-Tryptophan:2.5(w/v)%)を自由摂取させた。
B. breve OLB6129の投与期間の終了時に、血清中インドキシル硫酸の濃度を確認したところ、インドキシル硫酸の濃度の低減効果について、2 x 108 cfu/body/dayの投与群(III)と、2 x 109 cfu/body/dayの投与群(IV)では、生理食塩水の投与群(コントロール)(I)と比べて有意差があったが、2 x 107 cfu/body/dayの投与群(II)cfu/bodyでは、生理食塩水の投与群(コントロール)(I)と比べて有意差はなかった(図3)。
[実験手順]
Balb/cマウス(SLC, ♀, 6-week-old)を一週間で馴化した後に、表5のように、体重に基づいて 4群に分け、それぞれの群について、FOSを無添加の生理食塩水と生理食塩水の B. breve OLB6129(生菌)の懸濁液、FOSを添加した生理食塩水と生理食塩水の B. breve OLB6129(生菌)の懸濁液を、2週間で連続して午前中に経口投与した。馴化期間には全群に飼料(粉末CRF-1/L-Tryptophan:2.5(w/v)%)を自由摂取させた。なお、B. breve OLB6129(生菌)の濃度は、実施例3において、腐敗物質の低減効果に関して必要性が示された最低限の用量である、2 x 108 cfu/body/day に設定した。
FOSの投与期間の終了時に、血清中インドキシル硫酸の濃度を確認したところ、B. breve OLB6129のみの投与群では、インドキシル硫酸の濃度の低減効果は小さかった(図5)。また、インドキシル硫酸の濃度の低減効果について、FOSのみの投与群では、生理食塩水の投与群(I)と比べて有意差はなかった(図5)。一方、インドキシル硫酸の濃度の低減効果について、B. breve OLB6129とFOSの投与群では、生理食塩水の投与群(I)などと比べて有意差があった(図5)。なお、B. breve OLB6129のみの投与群と、B. breve OLB6129とFOSの投与群の2群(OLB6129 +)について、便中の B. breve OLB6129(投与菌)の菌数を測定したところ、FOSの投与群において生菌数が有意に高く観察された(図6)。
本明細書で引用した全ての刊行物、特許および特許出願をそのまま参考として本明細書にとり入れるものとする。
Claims (14)
- 腸内腐敗物質を低減させる、新規ビフィズス菌(Bifidobacterium breve)OLB6129(FERM BP-11257)。
- 請求項1記載のビフィズス菌を有効成分とする腸内腐敗物質の低減剤。
- フラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)を更に含む請求項2記載の腸内腐敗物質の低減剤。
- 請求項1記載のビフィズス菌を有効成分とする血清中のインドキシル硫酸の低減剤。
- フラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)を更に含む請求項4記載の血清中のインドキシル硫酸の低減剤。
- 請求項1記載のビフィズス菌を有効成分とする腸内腐敗物質の低減作用を有する食品。
- 請求項1記載のビフィズス菌を有効成分とするインドキシル硫酸の低減作用を有する食品。
- 請求項6又は7記載の食品を発酵乳製品又は発酵乳飲料とする食品。
- フラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)を更に含む請求項6~8のいずれか1項に記載の食品。
- 腸内腐敗物質を低減させる微生物の in vitro のスクリーニング方法において、微生物が殆ど増殖しない条件で、かつ腐敗物質の低減に必要な最低限のエネルギーとなるグルコースの濃度を反応液へ添加することを特徴とする、前記方法。
- グルコースの濃度を0.3~0.7(w/v)%とする請求項10記載の方法。
- 腸内腐敗物質を低減させる微生物の in vivo のスクリーニング方法であって、フラクトオリゴ糖(FOS)及び/又はガラクトオリゴ糖(GOS)、並びにトリプトファン(L-Tryptophan)を食餌へ添加し、マウスを飼育して、血清中のインドキシル硫酸の濃度を評価することを特徴とする、前記方法。
- フラクトオリゴ糖(FOS)の濃度及び/又はガラクトオリゴ糖(GOS)の濃度を0.5~20(w/v)%、並びにトリプトファンの濃度を1~4(w/v)%とする請求項12記載の方法。
- 微生物を乳酸菌及び/又はビフィズス菌とする請求項10~13のいずれか1項に記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012523872A JP5837879B2 (ja) | 2010-07-05 | 2011-07-05 | 腸内腐敗物質の低減作用を有するビフィズス菌 |
CN201180033393.0A CN102959075B (zh) | 2010-07-05 | 2011-07-05 | 具有肠内腐败物质的减少作用的双歧杆菌 |
HK13110266.1A HK1183058A1 (zh) | 2010-07-05 | 2013-09-03 | 具有腸內腐敗物質的減少作用的雙歧桿菌 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-152962 | 2010-07-05 | ||
JP2010152962 | 2010-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012005240A1 true WO2012005240A1 (ja) | 2012-01-12 |
Family
ID=45441219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/065350 WO2012005240A1 (ja) | 2010-07-05 | 2011-07-05 | 腸内腐敗物質の低減作用を有するビフィズス菌 |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP5837879B2 (ja) |
CN (2) | CN102959075B (ja) |
HK (2) | HK1183058A1 (ja) |
WO (1) | WO2012005240A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018193648A1 (ja) * | 2017-04-18 | 2018-10-25 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP2018177752A (ja) * | 2017-04-18 | 2018-11-15 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JPWO2018193648A1 (ja) * | 2017-04-18 | 2020-02-27 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP2020180094A (ja) * | 2019-04-26 | 2020-11-05 | 森永乳業株式会社 | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 |
WO2021079869A1 (ja) * | 2019-10-21 | 2021-04-29 | ビオフェルミン製薬株式会社 | 尿毒素軽減剤 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104988104B (zh) * | 2015-08-13 | 2017-12-26 | 山东凤凰生物有限公司 | 一株具有吸附或降解肠毒素功能的乳酸菌及其应用 |
CN106819107A (zh) * | 2016-12-29 | 2017-06-13 | 石家庄君乐宝乳业有限公司 | 具有整肠作用的发酵乳饮料及其制备方法 |
JP2022072243A (ja) | 2020-10-29 | 2022-05-17 | 帝人株式会社 | 腸内細菌叢改善用組成物及び腸内腐敗物質産生抑制用組成物 |
CN113005049B (zh) * | 2020-12-30 | 2022-11-01 | 江南大学 | 一株可缓解腹泻的短双歧杆菌及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05236945A (ja) * | 1992-02-27 | 1993-09-17 | Food Design Gijutsu Kenkyu Kumiai | 新規ラクトバチルス属微生物 |
JPH0856650A (ja) * | 1994-08-29 | 1996-03-05 | Meiji Seito Kk | 新規乳酸菌 |
JPH09234021A (ja) * | 1996-03-04 | 1997-09-09 | Meiji Milk Prod Co Ltd | 変異原性物質吸収阻害性食品 |
JPH11113564A (ja) * | 1997-10-14 | 1999-04-27 | Taiyo Corp | 抗変異原性を有する新規乳酸菌及びこれを含有する食品 |
JP2006158216A (ja) * | 2004-12-02 | 2006-06-22 | Miyarisan Kk | インドール減少能を有する微生物 |
WO2008019887A2 (en) * | 2006-08-18 | 2008-02-21 | Organobalance Gmbh | Probiotic microorganisms for the reduction of manure odor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE526711C2 (sv) * | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
JP2004277296A (ja) * | 2003-03-13 | 2004-10-07 | Morishita Jintan Kk | 乳酸菌含有腸溶性製剤 |
-
2011
- 2011-07-05 WO PCT/JP2011/065350 patent/WO2012005240A1/ja active Application Filing
- 2011-07-05 JP JP2012523872A patent/JP5837879B2/ja active Active
- 2011-07-05 CN CN201180033393.0A patent/CN102959075B/zh active Active
- 2011-07-05 CN CN201610085654.8A patent/CN105671120B/zh not_active Expired - Fee Related
-
2013
- 2013-09-03 HK HK13110266.1A patent/HK1183058A1/zh unknown
-
2015
- 2015-10-05 JP JP2015197460A patent/JP6096263B2/ja active Active
-
2016
- 2016-08-18 HK HK16109893.1A patent/HK1221748A1/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05236945A (ja) * | 1992-02-27 | 1993-09-17 | Food Design Gijutsu Kenkyu Kumiai | 新規ラクトバチルス属微生物 |
JPH0856650A (ja) * | 1994-08-29 | 1996-03-05 | Meiji Seito Kk | 新規乳酸菌 |
JPH09234021A (ja) * | 1996-03-04 | 1997-09-09 | Meiji Milk Prod Co Ltd | 変異原性物質吸収阻害性食品 |
JPH11113564A (ja) * | 1997-10-14 | 1999-04-27 | Taiyo Corp | 抗変異原性を有する新規乳酸菌及びこれを含有する食品 |
JP2006158216A (ja) * | 2004-12-02 | 2006-06-22 | Miyarisan Kk | インドール減少能を有する微生物 |
WO2008019887A2 (en) * | 2006-08-18 | 2008-02-21 | Organobalance Gmbh | Probiotic microorganisms for the reduction of manure odor |
Non-Patent Citations (1)
Title |
---|
TOSHIMASA YAMAMOTO ET AL.: "Effects of lactobacillus on the growth of human enteric saprogens", CLINICAL REPORT, vol. 20, no. 14, October 1986 (1986-10-01), pages 123 - 9 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018193648A1 (ja) * | 2017-04-18 | 2018-10-25 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP2018177752A (ja) * | 2017-04-18 | 2018-11-15 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JPWO2018193648A1 (ja) * | 2017-04-18 | 2020-02-27 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP7219898B2 (ja) | 2017-04-18 | 2023-02-09 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP7525868B2 (ja) | 2017-04-18 | 2024-07-31 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
JP2020180094A (ja) * | 2019-04-26 | 2020-11-05 | 森永乳業株式会社 | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 |
JP7309436B2 (ja) | 2019-04-26 | 2023-07-18 | 森永乳業株式会社 | 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 |
WO2021079869A1 (ja) * | 2019-10-21 | 2021-04-29 | ビオフェルミン製薬株式会社 | 尿毒素軽減剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2016028595A (ja) | 2016-03-03 |
HK1221748A1 (zh) | 2017-06-09 |
JP5837879B2 (ja) | 2015-12-24 |
CN105671120A (zh) | 2016-06-15 |
CN102959075A (zh) | 2013-03-06 |
CN105671120B (zh) | 2019-02-19 |
HK1183058A1 (zh) | 2013-12-13 |
JPWO2012005240A1 (ja) | 2013-09-02 |
CN102959075B (zh) | 2016-03-02 |
JP6096263B2 (ja) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6096263B2 (ja) | 腸内腐敗物質の低減作用を有するビフィズス菌 | |
JP5904688B2 (ja) | 共生乳酸産生細菌およびその使用 | |
JP6018625B2 (ja) | 高コレステロール血症の処置に使用するためのビフィドバクテリウム属に属する菌株 | |
JP5392672B2 (ja) | 新規の乳酸桿菌株及びその使用 | |
KR100514593B1 (ko) | 공역화 리놀렌산을 생산하는 신규한 균주, 이를 함유하는 캡슐제 및 이를 이용한 기능성 식품 | |
Campana et al. | Antagonistic activity of Lactobacillus acidophilus ATCC 4356 on the growth and adhesion/invasion characteristics of human Campylobacter jejuni | |
Saadatzadeh et al. | Probiotic properties of lyophilized cell free extract of Lactobacillus casei | |
KR101401530B1 (ko) | 공액리놀레산을 생산하는 비피도박테리움 롱검 균주 및 그 용도 | |
WO2019227418A1 (zh) | 一种组合物及其应用 | |
CN111329884B (zh) | 植物乳杆菌bc299在炎症性肠病、精神性问题的药物、食品中的应用 | |
US10813366B2 (en) | Bifidobacterium longum NCIMB 41676 | |
JP7012651B2 (ja) | ビタミンb12欠乏症を予防および/または治療するための組成物および方法 | |
CA2702293C (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
CA2908032A1 (en) | Composition containing bacterium belonging to genus lactobacillus | |
WO2019202033A1 (en) | Method for alleviating tobacco or nicotine withdrawal symptoms | |
KR101446309B1 (ko) | 공액리놀레산을 생산하는 비피도박테리움 애니말리스 균주 및 그 용도 | |
CN115484968A (zh) | 肠道双歧杆菌的生长的刺激 | |
KR20220059972A (ko) | 비타민 k2를 함유하는 유산균 발효물, 및 이를 포함하는 염증 예방 또는 치료용 조성물 | |
WO2019227414A1 (zh) | 一种组合物及其应用 | |
CA2831554A1 (en) | Lactobacillus strain onricb0240 and use of strain in methods and preparations to improve or maintain quality of life | |
CN107952062A (zh) | 动物用呼吸道防治药物及其制备方法 | |
TRUUSALU | KAI TRUUSALU |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180033393.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11803574 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012523872 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11803574 Country of ref document: EP Kind code of ref document: A1 |